The Commentary Magazine Podcast: "Inflation, the Economy, and Drugs"

Release Date: March 20, 2025

Introduction

In this episode of The Commentary Magazine Podcast, hosted by John Podhoretz, the discussion centers around the intricate interplay between inflation, the broader economy, and the pharmaceutical industry. Featuring esteemed guests David Bonson and Tevy Troy, alongside executive editor Abe Greenwald, the episode delves into the causes and implications of current economic trends, the impact of tariffs on various sectors, and the evolving dynamics within the pharmaceutical landscape.

Macroeconomic Landscape and Inflation Dynamics

Jerome Powell’s Statements and Tariff Implications

The conversation kicks off with an analysis of Jerome Powell's recent remarks aimed at calming economic uncertainties exacerbated by the Trump administration's tariff policies. John Podhoretz references a debate sparked by Breitbart's John Carney, questioning whether Powell attributed inflation directly to tariffs.

John Podhoretz [05:16]: "Jerome Powell... said... both the uncertainty and the failure of inflation to start restricting... was due in some measure to the tariffs that Trump is putting on."

David Bonson’s Insight on Inflation and Tariffs

David Bonson provides clarity, emphasizing that while tariffs themselves do not increase the money supply—a core driver of inflation per Milton Friedman's theory—they exert inflationary pressure by reducing production and increasing costs for goods like lumber, thereby impacting supply chains and investment.

David Bonson [08:13]: "Tariffs are inflationary... They put downward pressure on production... We have a supply side crisis in housing."

Bonson further critiques the internal divisions within the Trump administration, suggesting that disagreements between the Commerce and Treasury Departments hinder effective economic stabilization.

David Bonson [09:50]: "There's a philosophical disagreement within the administration... Chaos will lead to a better deal vs. chaos is unsettling for financial markets."

Housing Market and Regulatory Challenges

Impact of Tariffs on Construction

The discussion transitions to the housing sector, highlighting how tariffs on lumber—specifically a debated 25% tariff on Canadian lumber—could escalate construction costs and exacerbate the ongoing housing supply crisis.

David Bonson [16:16]: "A tariff on lumber would push prices higher and make access to the supply harder, impeding construction costs."

Regulatory Hurdles and Supply Constraints

John Podhoretz references Ezra Klein and Derek Thompson’s book Abundance, critiquing left-leaning policies that favor environmental regulations and zoning laws, which hinder housing development.

John Podhoretz [17:00]: "We have a growing population, we do not have a growing housing market... increased the price of housing through regulatory frameworks and neighborhood zoning."

Bonson concurs, advocating for YIMBYism (Yes In My Backyard) and deregulation to facilitate housing supply growth. He points out that much of the regulatory burden resides at the state and local levels rather than federal, underscoring the need for broader deregulation and financial incentives.

David Bonson [19:36]: "Financial deregulation is a big issue... private equity is willing to put in long term patient capital into the construction of new housing supply."

The conversation underscores the tension between regulatory oversight and the necessity of fostering an environment conducive to economic growth and housing affordability.

Pharmaceutical Industry: Challenges and Hostility

"In Praise of Big Pharma" by Tevy Troy

Tevy Troy introduces her lead article, "In Praise of Big Pharma," which defends the pharmaceutical industry against growing public and political hostility. The discussion highlights the industry's critical role in the economy, healthcare innovation, and its reliance on long-term investment.

Tevy Troy [26:18]: "Biomedical innovation... saves and improves and transforms people's lives."

Hostility and Its Economic Impact

The guests examine the increasing antagonism towards Big Pharma from both Democrats and Republicans, attributing it to high-profile trial lawsuits, regulatory burdens, and the perception of excessive drug pricing.

Tevy Troy [27:43]: "Republicans are now joining Democrats and Hollywood in bashing pharmaceuticals."

Direct-to-Consumer Advertising

A significant portion of the discussion focuses on the consequences of pharmaceutical companies' decision to engage in direct-to-consumer (DTC) advertising. This strategy, intended to boost drug adoption, has backfired by fostering public resentment and complicating doctor-patient dynamics.

Tevy Troy [56:01]: "These DTC ads... make consumers go to the doctor and pressure them to prescribe these high-priced drugs."

Bonson draws parallels between pharma advertising and hedge fund marketing, noting that both target audiences who may not fully grasp the implications of their choices.

David Bonson [54:35]: "Pharmaceutical advertising is meant to impact the pressure we put on our own doctors."

Innovation, AI, and the Future of Pharmaceuticals

AI’s Role in Drug Development

Tevy Troy envisions a future where artificial intelligence revolutionizes pharmaceutical research by simulating drug outcomes, thereby reducing the risks and costs associated with traditional drug testing.

Tevy Troy [58:43]: "AI could help predict drug efficacy early in the process, avoiding costly failures."

Bonson echoes this optimism, suggesting that AI and informatics could streamline regulatory processes and accelerate the approval of innovative therapies.

David Bonson [59:34]: "AI can also help on the regulatory front... we can get approvals to come through faster."

Barriers to Innovation

Despite the potential, the episode highlights significant barriers such as high regulatory costs, legal challenges, and public hostility, which deter investment and stifle innovation.

Tevy Troy [36:32]: "High prices are a result of regulatory and legal costs... it's math, not greed."

Bonson emphasizes the precarious balance pharmaceutical companies must maintain to fund R&D while managing public perception and legal liabilities.

David Bonson [45:20]: "Investment capital for pharma is high-risk... it's either going to pay off big or you're losing everything."

Global Competition and America's Pharmaceutical Dominance

International Rivalry and Regulation

The episode explores the global landscape, questioning whether countries like China or smaller nations such as Denmark could outpace the U.S. in pharmaceutical innovation by adopting less stringent regulations.

John Podhoretz [63:02]: "What if Brazil decides to go radically in the other direction and becomes a pharmaceutical powerhouse?"

Tevy Troy warns that regulatory strictness in the U.S. might drive talent and investment abroad, particularly to countries willing to bypass the rigorous standards that ensure drug safety and efficacy.

Tevy Troy [66:38]: "40% of the scientific workers at pharmaceutical companies in America are immigrants... they might leave if the environment becomes inhospitable."

Bonson draws parallels to financial markets, suggesting that overly stringent regulations can push industries overseas, undermining domestic competitiveness.

David Bonson [64:12]: "Global competitiveness keeps countries in check... deregulation in pharma could spur international innovation."

China’s Potential Supremacy

The conversation touches on the potential for China to dominate the pharmaceutical sector if the U.S. continues its hostile stance, noting that Chinese regulatory environments may prioritize speed over safety.

Tevy Troy [67:55]: "China wipes away regulations to meet demands quickly, which could compromise drug safety but boost production."

Podhoretz underscores the risks of such an approach, emphasizing the importance of maintaining high standards to prevent industrial mishaps that could have global repercussions.

John Podhoretz [64:52]: "Facilities in China might cut corners, leading to widespread health crises."

Cultural Perceptions and Media Influence

Pharma Representation in Media

Abe Greenwald and Tevy Troy discuss how pharmaceuticals are portrayed as villains in popular media, contributing to public distrust and hostility.

John Podhoretz [49:00]: "You're more likely to see a pharmaceutical exec as a bad guy than some kind of Russian agent."

Greenwald reflects on the disconnect between professional depiction and public perception, questioning why pharma is consistently villainized.

Abe Greenwald [50:59]: "Traditional medicine was about doctor-patient trust, not selling to consumers."

Consequences of Negative Portrayals

The negative media portrayal hampers the industry's reputation, making it difficult to attract young talent and secure public support for innovative projects.

Tevy Troy [55:41]: "Our war against pharma is hurting the ability to get the fruition of this possibility."

Conclusion

The episode wraps up with John Podhoretz reiterating the critical nature of pharmaceutical innovation to the economy and public health. He underscores the necessity of addressing regulatory and public perception challenges to maintain America’s leadership in this vital sector.

John Podhoretz [67:55]: "We have an unprecedented opportunity in pharma, but internal conflicts are jeopardizing our future."

Tevy Troy and David Bonson echo the call for a balanced approach that fosters innovation while ensuring safety and ethical standards, highlighting the delicate interplay between regulation, public perception, and economic policy.

Tevy Troy [68:05]: "AI can transform biomedical research, but hostility towards pharma must be mitigated to realize its full potential."

The episode concludes with a promotional segment for Commentary's new limited edition merchandise, symbolizing the unyielding commitment to addressing and navigating the complexities of today's economic and pharmaceutical landscapes.

Notable Quotes

• John Podhoretz [05:16]: "Jerome Powell... is trying to calm people about the economic uncertainty introduced by Trump's tariffs."

• David Bonson [08:13]: "Tariffs are inflationary... they put downward pressure on production."

• Tevy Troy [27:43]: "Republicans are now joining Democrats and Hollywood in bashing pharmaceuticals."

• Tevy Troy [56:01]: "These DTC ads... make consumers go to the doctor and pressure them to prescribe these high-priced drugs."

• Tevy Troy [58:43]: "AI could help predict drug efficacy early in the process, avoiding costly failures."

• Tevy Troy [66:38]: "40% of the scientific workers at pharmaceutical companies in America are immigrants..."

• John Podhoretz [67:55]: "We have an unprecedented opportunity in pharma, but internal conflicts are jeopardizing our future."

Key Takeaways

1. Economic Policies and Inflation: Tariffs, while intended to protect domestic industries, can inadvertently stoke inflation by increasing production costs and creating supply chain uncertainties.

2. Housing Market Challenges: Regulatory hurdles at state and local levels significantly impede housing supply growth, exacerbating affordability issues and economic disparities.

3. Pharmaceutical Industry Pressures: Growing hostility towards Big Pharma—fueled by legal challenges and negative media portrayals—threatens innovation and the industry's ability to contribute meaningfully to public health and economic growth.

4. Role of AI in Innovation: Artificial intelligence holds promise in revolutionizing drug development, potentially reducing costs and accelerating the availability of life-saving medications.

5. Global Competitive Landscape: Without addressing internal regulatory and perceptual challenges, the U.S. risks ceding pharmaceutical dominance to more flexible and less regulated international competitors.

6. Cultural Perceptions Matter: Media representations and public sentiment play a crucial role in shaping the pharmaceutical industry's future, affecting everything from talent acquisition to investment and innovation.

This summary encapsulates the multifaceted discussions from The Commentary Magazine Podcast episode "Inflation, the Economy, and Drugs," providing listeners with a comprehensive overview of the key themes and insights shared by the hosts and guests.